Sterile Medical Packaging Market to Reach $42.85 Billion with 7.07% CAGR Forecast to 2022

Global Sterile Medical Packaging market is accounted for $26.55 billion in 2015 and is expected to reach $42.85 billion by 2022 growing at a CAGR of 7.07%

PUNE, INDIA, March 1, 2017 /EINPresswire.com/ — Summary

Wiseguyreports.Com Adds “Sterile Medical Packaging – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 – 2022”

Global Sterile Medical Packaging market is accounted for $26.55 billion in 2015 and is expected to reach $42.85 billion by 2022 growing at a CAGR of 7.07%. Rising Adoption of Sterile packaging in packaging of medical equipment, pharmaceutical and biological products is one of the major factors driving the market. Factors such as rising healthcare awareness and disposable income are further fueling the market. However, maintaining medical packaging integrity is restricting the market growth.

Request a Sample Report @ https://www.wiseguyreports.com/sample-request/674322-sterile-medical-packaging-global-market-outlook-2016-2022

Pharmaceuticals and Biologics segment is expected to witness a highest share during the forecast period owing to its applications. North America accounted for the largest share in the market. Moreover, Asia Pacific is expected to witness the highest CAGR during the forecast period. The favourable growth is attributed to rising healthcare awareness and technological advancements.

Some of the key players in global sterile medical packaging market include ALARIS Medical Systems, Honeywell International Incorporated, 3M Company, ESCO Technologies Incorporated, Becton, Dickinson and Company, Kimberly-Clark Corporation, Bemis Company Incorporated, Alcan Incorporated, Intercome Packaging Company Limited, Ethox Corporation, Abbott Laboratories, Gerresheimer Glass Inc., Baxter International Incorporated, Alcoa Incorporated, Unicep Packaging, Inc., and Amcor Limited.

Sterilization Methods Covered:
• Radiation
• Chemical
• Other Sterilization Methods

Applications Covered:
• Medical Equipment
o Therapeutic Equipment
o Diagnostic
o Surgical Equipment
• Pharmaceuticals & Biologics
• Medical Supplies
o Surgical Tapes
o Scissors
o Gloves
o Syringes and Needles

Materials Covered:
• Nonwoven
• Glass
• Plastic
• Foam Sheets
• Paper
• Foil
• Other Materials

Products Covered:
• Clamshell and Lids
• Prefillable Syringes
• Bottles
• Vials and Ampoules
o Pouches & Bags
o Liner Tear Bags
o Spout Pouches
o Gusset Bags
o Header Bags
o Semi Ultra Clean Bags
• IV Containers
• Thermoform Trays
• Other Products

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o France
o Italy
o UK
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o Rest of Asia Pacific
• Rest of the World
o Middle East
o Brazil
o Argentina
o South Africa
o Egypt

……

At any Query @ https://www.wiseguyreports.com/enquiry/674322-sterile-medical-packaging-global-market-outlook-2016-2022

1 Executive Summary

2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions

…..

11 Company Profiling
11.1 ALARIS Medical Systems
11.2 Honeywell International Incorporated
11.3 3M Company
11.4 ESCO Technologies Incorporated
11.5 Becton, Dickinson and Company
11.6 Kimberly-Clark Corporation
11.7 Bemis Company Incorporated
11.8 Alcan Incorporated
11.9 Intercome Packaging Company Limited
11.10 Ethox Corporation
11.11 Abbott Laboratories
11.12 Gerresheimer Glass Inc.
11.13 Baxter International Incorporated
11.14 Alcoa Incorporated
11.15 Unicep Packaging, Inc.
11.16 Amcor Limited

Buy Now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=674322

What our report offers:
– Market share assessments for the regional and country level segments
– Market share analysis of the top industry players
– Strategic recommendations for the new entrants
– Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets
– Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
– Strategic recommendations in key business segments based on the market estimations
– Competitive landscaping mapping the key common trends
– Company profiling with detailed strategies, financials, and recent developments
– Supply chain trends mapping the latest technological advancements

Continued….

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Global Nylon 6 Market Segment by Applications, Product Type And Forecast To 2022

Nylon 6, is a polymer developed by Paul Schlack at IG Farben to reproduce the properties of nylon 6.6 without violating the patent on its production.

PUNE, INDIA, March 1, 2017 /EINPresswire.com/ — Global Nylon 6 Market

Scope of the Report:
This report focuses on the Nylon 6 in Global Market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Get Sample Report @ https://www.wiseguyreports.com/sample-request/1005454-global-nylon-6-market-by-manufacturers-countries-type-and-application-forecast

Market Segment by Manufacturers, this report covers
BASF SE
Honeywell
Royal DSM N.V
Lanxess
Clariant Corporation
Unitika
DOMO Chemicals
Firestone Textiles Company
Grupa Azoty
LIBOLON
Polymeric Resources Corporation
UBE
EMS-Grivory
Shakespeare

Market Segment by Regions, regional analysis covers
North America (USA, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Columbia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers
Standard Nylon 6
Reinforced Nylon 6

Market Segment by Applications, can be divided into
Automotive Industry
Electronics & Electrical
Packaging Industry
Others

Complete Report Details @ https://www.wiseguyreports.com/reports/1005454-global-nylon-6-market-by-manufacturers-countries-type-and-application-forecast

Table of Contents -Major Key Points

1 Market Overview
1.1 Nylon 6 Introduction
1.2 Market Analysis by Type
1.2.1 Standard Nylon 6
1.2.2 Reinforced Nylon 6
1.3 Market Analysis by Applications
1.3.1 Automotive Industry
1.3.2 Electronics & Electrical
1.3.3 Packaging Industry
1.3.4 Others
1.4 Market Analysis by Regions
1.4.1 North America (USA, Canada and Mexico)
1.4.1.1 USA Market States and Outlook (2012-2022)
1.4.1.2 Canada Market States and Outlook (2012-2022)
1.4.1.3 Mexico Market States and Outlook (2012-2022)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2012-2022)
1.4.2.2 France Market States and Outlook (2012-2022)
1.4.2.3 UK Market States and Outlook (2012-2022)
1.4.2.4 Russia Market States and Outlook (2012-2022)
1.4.2.5 Italy Market States and Outlook (2012-2022)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2012-2022)
1.4.3.2 Japan Market States and Outlook (2012-2022)
1.4.3.3 Korea Market States and Outlook (2012-2022)
1.4.3.4 India Market States and Outlook (2012-2022)
1.4.3.5 Southeast Asia Market States and Outlook (2012-2022)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2012-2022)
1.4.4.2 Egypt Market States and Outlook (2012-2022)
1.4.4.3 Saudi Arabia Market States and Outlook (2012-2022)
1.4.4.4 South Africa Market States and Outlook (2012-2022)
1.4.4.5 Nigeria Market States and Outlook (2012-2022)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force

2 Manufacturers Profiles
2.1 BASF SE
2.1.1 Business Overview
2.1.2 Nylon 6 Type and Applications
2.1.2.1 Type 1
2.1.2.2 Type 2
2.1.3 BASF SE Nylon 6 Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Honeywell
2.2.1 Business Overview
2.2.2 Nylon 6 Type and Applications
2.2.2.1 Type 1
2.2.2.2 Type 2
2.2.3 Honeywell Nylon 6 Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Royal DSM N.V
2.3.1 Business Overview
2.3.2 Nylon 6 Type and Applications
2.3.2.1 Type 1
2.3.2.2 Type 2
2.3.3 Royal DSM N.V Nylon 6 Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Lanxess
2.4.1 Business Overview
2.4.2 Nylon 6 Type and Applications
2.4.2.1 Type 1
2.4.2.2 Type 2
2.4.3 Lanxess Nylon 6 Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 Clariant Corporation
2.5.1 Business Overview
2.5.2 Nylon 6 Type and Applications
2.5.2.1 Type 1
2.5.2.2 Type 2
2.5.3 Clariant Corporation Nylon 6 Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

………..CONTINUED

Buy Now@ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=1005454

CONTACT US :

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

18,500 Risperdal lawsuits filed nationwide, says J&J's new annual report


Schmidt National Law Group now accepting cases

Schmidt National Law Group

Litigation surrounding the antipsychotic drug expected to continue to grow

SAN DIEGO, CALIFORNIA, UNITED STATES, March 1, 2017 /EINPresswire.com/ — 18,500. That’s how many Risperdal lawsuits are pending against Johnson & Johnson and its subsidiary Janssen Pharmaceuticals nationwide, according to J&J’s latest annual report filed Monday.

The lawsuits stem from allegations the companies’ antipsychotic drug Risperdal can cause breast growth in young boys, a condition known as gynecomastia.

J&J says it continues to receive information about the anticipated number of Risperdal cases and expects more lawsuits to be filed in the future. In other words, the number 18,500 could become even bigger.

The majority of Risperdal lawsuits are filed in state courts in California, Pennsylvania, and Missouri, but more are filed in courts across the country.

The giant mass tort centralized in Philadelphia’s Court of Common Pleas has already rendered multimillion-dollar verdicts against J&J and Janssen.

The largest Risperdal verdict out of Philadelphia – a massive $70 million judgment – was handed down in July 2016 in favor of a Tennessee boy who developed gynecomastia after taking Risperdal. The award was later increased to $76 million and is on appeal in Pennsylvania’s Superior Court.

Janssen has since settled several Risperdal cases in the days leading up to their scheduled jury trials.

In spite of these multimillion-dollar verdicts and undisclosed settlements, J&J says it doesn’t expect the litigation to have a huge impact on its bottom line.

In its annual report, J&J wrote:

“In the Company's opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings … is not expected to have a material adverse effect on the Company's financial position.”

But Risperdal lawsuits aren't the only litigation J&J and its various subsidiaries are currently fighting. The conglomerate faces thousands of lawsuits involving its DePuy and Pinnacle hip implants, baby powder product, blood thinning drug Xarelto, and over 54,000 pelvic mesh lawsuits.

Still, J&J believes “it has substantial defenses in these matters,” according to its annual report.

About Risperdal & Risperdal Lawsuits

Risperdal is an antipsychotic medication used to treat schizophrenia, symptoms related to bipolar disorder and autism, and other mental health disorders.

It was approved by the U.S. Food and Drug Administration in 1993 for the treatment of schizophrenia in adults. It would not be approved for treatment in children until 2006, despite being prescribed off-label to kids for a number of years.

In 2013, Janssen agreed to pay more than $1.39 billion as part of a settlement agreement resolving claims it illegally marketed Risperdal for use in children, among other allegations.

Risperdal patients who experienced side effects like gynecomastia may be able to file a Risperdal lawsuit of their own. Schmidt National Law Group is currently seeking claimants and is in the process of filing claims related to Risperdal and gynecomastia. Contact us today at 1-800-214-1010 or visit our website to learn more.

About Schmidt National Law Group

Schmidt National Law Group is a personal injury firm located in San Diego, Calif. Its team of experienced attorneys represents victims of all types of injuries, including those harmed by pharmaceutical drugs and medical devices.

Schmidt National Law Group’s team of attorneys, medical professionals, writers, and case managers fight every day for the rights of the injured. Martin Schmidt, a trial attorney with 30 years experience, has been recognized as a leading personal injury attorney and was chosen as one of the "Top 100 Trial Lawyers" by the American Association for Justice in 2015 and 2016.

Contact Us

Schmidt National Law Group
http://www.nationalinjuryhelp.com/
4241 Jutland Drive, Suite 200, San Diego CA, 92117
1-800-214-1010

Melissa Beltz
Schmidt National Law Group
800-214-1010 Ext. 370
email us here


Source: EIN Presswire

Intermountain Healthcare Names Chief Patient Safety and Experience Officer

SALT LAKE CITY, UTAH, USA, March 1, 2017 /EINPresswire.com/ — Shannon Connor Phillips, MD, MPH, has been named as Intermountain Healthcare’s Chief Patient Safety and Experience Officer. In this role, Dr. Phillips will work collaboratively with other Intermountain leaders to continually improve outcomes, safety, and the patient experience.

Dr. Phillips comes to Intermountain from Cleveland Clinic, where she is a physician lead in the Office of Clinical Transformation. She also served as Associate Chief Quality Officer and previously as the organization’s first Patient Safety Officer. In addition, she is on the National Quality Forum Expert Panel on Common Formats, a group focused on development of a national standard and repository for patient safety events. Dr. Phillips is recognized nationally and internationally for her expertise and leadership in safety, quality improvement, and culture in healthcare.

Dr. Phillips is a pediatrician and pediatric hospitalist with an interest in children with special healthcare needs. She joined Cleveland Clinic in 2004 to develop and lead a pediatric hospitalist medicine program and served as the first Cleveland Clinic Director of Pediatric Hospital Medicine. Previously, Dr. Phillips served at Riley Children’s Hospital in Indiana and Children’s Hospital of Philadelphia.

Dr. Phillips earned her medical degree from Columbia University College of Physicians & Surgeons in New York and her undergraduate degree from Emory College in Atlanta. She completed a pediatric internship and residency at George Washington University Children’s National Medical Center, in Washington, D.C. In addition, she earned a Master of Public Health degree at the Bloomberg School of Public Health, Johns Hopkins University.

Intermountain Healthcare is a Utah-based not-for-profit system of 22 hospitals, 185 clinics, a Medical Group with about 1,500 employed physicians and advanced practitioners, a health plans group called SelectHealth, and other medical services. Intermountain is widely recognized as a leader in transforming healthcare through high quality and sustainable costs. For more information about Intermountain, visit www.intermountainhealthcare.org.

Daron Cowley
Intermountain Healthcare
801-442-2834
email us here


Source: EIN Presswire

New Health Insurance Leads Service Provided By Challenger Marketing To Change The Face Of Insurance As We Know It

New Launch Of Health Insurance Leads
Service From Challenger Marketing, This new development will be worth paying attention to, as it's set to shake things up.

VALLEY COTTAGE, NEW YORK, USA, February 28, 2017 /EINPresswire.com/ — This week, Challenger Marketing announced the launch of its new Health Insurance Leads service, set to go live 26-Feb-2017. For anyone with even a passing interest in the world of Insurance, this new development will be worth paying attention to, as it's set to shake things up in the Health Insurance Industry.

Currently, while everyone else is giving leads out from internet forms and emails, the sales reps then have to waste a lot of time calling up the prospects until they finally reach them. This could take the sales rep multiple attempts.
Sales prospects can now be delivered live to the sales agent saving them a lot of time .

The Director at Challenger Marketing, Mohamed Alwakeel, makes a point of saying "Things are going to change when our Health Insurance Leads service launches".
Mohamed Alwakeel continues… "Where you'll always see our competitors doing the same old thing, we will work with our customers to emsure they receive great quality targeted leads. We do this because we want to innovate and help our customers. Ultimately this is going to be a huge benefit to our customers because It will save money and time for our them ."

Challenger Marketing was established in 2009. It has been doing business since 2009 and it has always aimed to Provide premium marketing services to business.
Currently, many other Lead Generation companies get leads from the internet and send emails with the prospects details to the sales agent, but Challenger Marketing improved on this by Live lead transfer instead of an email with the prospects details. This alone is predicted to make Challenger Marketing's Health Insurance Leads service more popular with customers in the Insurance space, quickly.

Once again, the Health Insurance Leads service launched on 26-Feb-2017. To find out
more, the place to visit is here.

Mr Mohamed Alwakeel
Challenger Marketing
845-767-7472
email us here


Source: EIN Presswire

New York State legislature to recognize World Lymphedema Day™ and honor advocates

Actor and LE&RN Honorary Board Member Steve Guttenberg will be honored in Albany, NY, on March 2, 2017

Actor and LE&RN Honorary Board Member Steve Guttenberg will be honored in Albany, NY, on March 2, 2017

Nicole Faccio with her fundraising team, In Pizza We Crust, at the Brooklyn Bridge in September 2016

Nicole Faccio with her fundraising team, In Pizza We Crust, at the Brooklyn Bridge in September 2016

Nicole Faccio, center, with her 2016 fundraising team, In Pizza We Crust

Nicole Faccio, center, with her 2016 fundraising team, In Pizza We Crust

LE&RN representatives to attend World Lymphedema Day event in Albany, NY, on March 2

I am advocating for the need to increase funding for research, tools that will increase education, access to affordable treatments and, eventually, a cure.”

— Nicole Faccio, LE&RN Member and Activist

NEW YORK, NY, USA, February 28, 2017 /EINPresswire.com/ — New York State has been a leader in the fight against lymphedema and lymphatic diseases, led by such champions in the New York State legislature as Assemblymember Linda B. Rosenthal and Senator Martin J. Golden. In 2016, the State was the first legislative body in the nation and in the world to establish March 6 as World Lymphedema Day.

This year, New York State will pass a resolution recognizing March 6 as World Lymphedema Day, and will honor two New York State lymphatic disease advocates. Actor Steve Guttenberg, whose mother suffers from lymphedema, became a LE&RN Honorary Board member at the 2016 Brooklyn Walk. Nicole Faccio, a LE&RN member who recruited over 50 supporters for her 2016 New York Walk team at the Brooklyn Bridge last September, was born with primary LE (lymphedema) in both legs and in her left arm, which then resulted with the collapse of her lung due to fluid accumulation on the pleura.

“I am lucky in many ways,” Nicole said. “I was diagnosed early and received excellent care. As a result, lymphedema hasn’t stopped me from living to the fullest, including attending college to become an Engineer, traveling, living abroad, and having a career in NYC. Many people aren’t that fortunate, and lymphedema and lymphatic diseases are too often undiagnosed and untreated. I found out about the New York Walk to Fight Lymphedema & Lymphatic Diseases just a week before the event. In Pizza We Crust (my fundraising team) raised over $4,000. That gave me the courage to tell my story.”

Nicole is honored to be recognized in Albany and will continue to share her experience to inspire others to do the same. She aims to increase awareness of lymphedema and lymphatic diseases, and hopes to serve as an example of the product of proper care.

“I ask our leaders to invest in quality of life for millions of citizens who deserve access to proper and affordable treatment,” Nicole said. “I am advocating for the need to increase funding for research, tools that will increase education, access to affordable treatments and, eventually, a cure.”

These resolutions will be read at the Statehouse in Albany on March 2. Representatives of LE&RN, including honoree Nicole Faccio, will be in attendance.

About LE&RN
Founded in 1998, the Lymphatic Education & Research Network (formerly LRF) is a 501(c)(3) not-for profit organization whose mission is to fight lymphatic disease and lymphedema through education, research and advocacy. LE&RN provides valuable educational resources for the millions of people who suffer from lymphedema and lymphatic disease. LE&RN fosters and supports research that can deepen the medical community's understanding of the lymphatic system. For more information about lymphatic disease or the Lymphatic Education & Research Network, visit www.LymphaticNetwork.org.

Laura Farrell
Lymphatic Education & Research Network
(516) 625-9675
email us here

Watch: New York State leads the way in lymphedema and lymphatic disease awareness and advocacy


Source: EIN Presswire

Cambia Dental Lab Expands Management Pedigree

Recruits Eric Bergio to Supervise Rapidly Expanding Digital Services Department

Our management team continues to find success recruiting key industry technicians, managers and executives which I believe is the result of our current growth trajectory and clear corporate vision.”

— Bill Selvig, Vice President of Manufacturing and Co-Owner

LAKE FOREST, CALIFORNIA, USA, February 28, 2017 /EINPresswire.com/ — Cambia Dental Lab (www.cambiadentallab.com) announced today that Eric Bergio has joined the Company to further develop their growing suite of digital dental solutions including their hugely popular implant treatment planning capabilities. Eric Bergio brings a wealth of experience within the dental industry, having spent the last 10 years working for several top tier dental implant companies like Biomet 3i, and quality dental labs such as DSG Yankee Dental Lab and Winter Lab. Eric joins Cambia Dental Lab at a time when the Company is experiencing hyper growth within its implant business allowing him to continue his industry success.

“Our management team continues to find success recruiting key industry technicians, managers and executives which I believe is the result of our current growth trajectory and clear corporate vision,” said Bill Selvig, Cambia Dental Lab’s Vice President of Manufacturing and Co-Owner. “Eric is going to be a superstar,” he continued. “He has an excellent balance of industry experience and perhaps the greatest work ethic of any person in this industry that I have met to date. He brings experience, knowledge and a deep passion for digital and implant dentistry that fits right in our wheel house”.

Cambia Dental Lab recently announced a 2 year exclusive deal with MyPractice9 (www.mypractice9.com), a web-based company which connects private practice dentists with local itinerant dental specialists. According to the Company, that partnership has resulted in a continual flux of significant new business. As MyPractice9 expands nationally that trend is likely to accelerate.

“The national landscape of dental labs has changed from a largely hand-crafted business to a robust light industrial manufacturing enterprise,” Selvig stated. “However, the ubiquitous nature of milling systems has virtually eliminated technical quality as a value proposition. Companies must look further into the future and deeper within their collective organizations to determine their unique place in the market. That is what we have done. Our industry focus and corporate rebranding has re-energized our organization in a way that people are noticing. Every time we add a high caliber member to our team like Eric, it’s like turbo charging our vision. It is just incredibly exciting around here,” he added.

Cambia Dental Lab is based in Lake Forest, California. The Company provides dental lab services including a full complement of implant and digital planning and design services to dental professionals nationwide.

MyPractice9 is a web based company which connects U.S. dentists with local traveling dental specialists for the purpose of providing in-practice specialty dental services.

Heather Pritchard
Cambia Dental Lab
877-422-6242
email us here


Source: EIN Presswire

BergaMet NA Products Now Available on Amazon.com

BergaMet NA Products Now Available on Amazon.com

LAS VEGAS, NEVADA, UNITED STATES, February 28, 2017 /EINPresswire.com/ — BergaMet NA Products Now Available on Amazon.com
Copmany’s metabolic syndrome products available on major online retailer

BOCA RATON, Fla.— BergaMet NA, a company that creates a line of products that improves the lives of people who suffer from metabolic syndrome, announced its products are now available for purchase on Amazon.com, the world’s largest online retailer.

BergaMet NA’s product line is large and varied, but all of its offerings are based on high-quality natural ingredients sourced from all over the world. The company’s premier product, BergaMet, has developed a reputation as the best citrus bergamot product currently available in its market. Now, this product has arrived on Amazon.com, which gives the company a larger audience than ever before.

“We are thrilled to announce that BergaMet is now available for purchase on Amazon.com,” said Logan Decker, Director of Operations for BergaMet NA. “These natural products are extremely useful for helping people find some much-needed relief from their metabolic syndrome symptoms. We are pleased to have the chance to reach out to more people than ever before to provide them with these benefits.”

BergaMet NA was established in early 2016 after its founders learned about the bergamot citrus grown in the Calabrian region of Italy. Researchers closely analyzed some of the clinical trials that had been performed on the fruit and found that it was a natural cardiovascular supplement thanks to its high levels of polyphenols. Bergamot can be grown in various places and climates around the world, but only those Italian fruits have this unique polyphenol composition.

Today, BergaMet offers several options for its supplements, each of which targets different health issues. BergaMet Mega+O, for example, is particularly useful for consumers who have high LDL cholesterol, low HDL cholesterol and high triglyceride levels. Another common choice among BergaMet customers is BergaMet Sport, which provides the same benefits as Mega+O but with an 18 percent stronger effect. Bergamet Sport also helps athletes improve energy levels, improve muscle recovery and athletic performance.

“We are eager to continue expanding our brand reach so we can help more people around the world achieve better metabolic and cardiovascular health,” said Decker.

For more information about BergaMet NA and its products, visit www.bergametna.com.

Logan Decker
BergaMet NA
3038429765
email us here


Source: EIN Presswire

Omega Skin Solutions Announces Licensing Deal

ALLENTOWN, PENNSYLVANIA, USA, February 28, 2017 /EINPresswire.com/ — Omega Skin Solutions announced a licensing deal with a private equity firm. Under the terms of the deal, the private equity firm will acquire, develop, and market Omega's products for acne, hair loss, wrinkles and other skin blemishes. In return, Omega will receive milestone payments and 10% of sale revenue.

Dr Ketan Desai, chairperson of the board, said "It is great to have a successful exit only four years after incorporation in such a competitive market. I have no doubt that our lead product will become the market leader in Acne treatment within a few years".

Omega Skin Solutions is a Pennsylvania based corporation developing products for skin care. It has patents awarded for various skin diseases and has undertaken studies to support them. The lead product, OSS1, had demonstrated superiority to ProActive® in a study

The name of the private equity firm was not disclosed. The deal was signed on October 11 in Maryland, USA. For further information, contact Ketan Desai

Ketan Desai
Omega SS
610-252-8240
email us here


Source: EIN Presswire

Personal Importation:Time for Congress, Administration to pass legislation on behalf of American patients

Letters to HHS Secretary seeking executive action on 2003 legislation have good intentions, but time for Congress to act to lower prescription prices

ST. LOUIS, MO, USA, February 28, 2017 /EINPresswire.com/ — The publisher of RxforAmericanHealth and AmericanRxBillofRights says that while a recent letter from Senators Amy Klobuchar (D-MN), Charles Grassley (R-IA) and John McCain (R-AZ) to Health and Human Services(HHS) Secretary Tom Price asking him to utilize legislation crafted 14 years ago to exercise his authority to ‘enable’ personal importation of prescription medicines under provisions of the Medicare Prescription Drug Improvement and Modernization Act of 2003, is ‘admirable’, it reflects the fact of the failure of Congress to overcome the opposition of Pharma, which views personal importation as a threat to its ability to impose the highest prescription drug prices in the world upon American patients.

Daniel Hines noted that “The Senators are not alone in making such a request. A group of 33 Democrat members of the House of Representatives sent a similar appeal to President Obama, asking him to issue an executive order shortly before the end of his Presidency.”

“Also, throughout the last 14 years, advocates for personal importation, including me, have challenged previous HHS Secretaries to act on specific portions of the legislation,” Hines says.

“The significant portions are that Congress directed that: ’The Secretary, in consultation with appropriate government agencies, shall conduct a study on the importation of drugs into the United States pursuant to section 804 of the Federal Food, Drug, and Cosmetic Act (as added by section 1121 of this Act). Not later than 12 months after the date of the enactment of this Act, the Secretary shall submit to the appropriate committees of the Congress a report providing the findings of such study’ and, ‘…In particular, the Secretary shall by regulation grant individuals a waiver to permit individuals to import into the United States a prescription drug that—(A) is imported from a licensed pharmacy for personal use by an individual, not for resale, in quantities that do not exceed a 90-day supply; (B) is accompanied by a copy of a valid prescription; C) is imported from Canada, from a seller registered with the Secretary; ‘(D) is a prescription drug approved by the Secretary under chapter V’ ”.

Hines says these provisions are an early indication of the fact that there was—and remains today—a realization by Congress that even in 2003, relief was needed for the millions of Americans who were then—and today—denied access to safe, affordable brand-name prescription medicines from licensed, registered pharmacies in Tier One Countries whose standards of safety and efficacy meet or exceed those of the U.S.

“Significantly, although the HHS Secretaries over the years chose not to act on the legislation, American patients acted on their own initiative, and by so doing have provided a de facto validation of the authenticity, efficacy, and validity of personal importation of brand-name medicines from Tier One Countries of which Canada is one” Hines continues.

But, he says that it is now time for Congress to enact legislation that meets the current needs of American patients.
“New legislation is needed because there exists the potential that one provision of the 2003 Act—a role for wholesalers and pharmacies– that is not only unnecessary but could be actually harmful to the health and well-being of American patients, increase prices and establish a framework to give price control to a new entity of wholesalers and pharmacies.

“A provision in the 2003 act would empower the HHS Secretary to establish wholesale operations within the U.S., solely for the importation of medicines from Canada to be resold in the U.S., as well as allowing specific pharmacies to engage in personal importation,” he explains.

“This was opposed by many proponents of personal importation when it was first presented in the 2003 legislation.”
He cites several reasons for concern about this segment of the 14-year-old bill:
· One of the debates that arose about personal importation from Canada in 2003, was a reaction from some Canadian officials being fearful that Canada would become ‘America’s drugstore’ a concern that can be directly linked to the wholesaling provision;
· Equally pertinent, many American advocates of personal importation believed then, and continue to do so today, that to grant such blanket authority to wholesalers and pharmacies would defeat the very purpose of personal importation, i.e., individual American patients’ access to safe, affordable brand-name medicines;
· And, he says we must be concerned about U.S. wholesalers gaining control over large supplies or sources of lower-cost medicines, giving them a capability to control prices in a manner similar to the abusive practices of Pharma, thereby crippling the ability of Americans to make purchases of their ‘imported’ meds from any source other than wholesalers and pharmacists.

“That’s why it is time for Congress, especially those erstwhile supporters of personal importation to come together to form a consensus on comprehensive legislation for personal importation of prescription medicines as the only readily available avenue with which to ensure that no American is denied their access to vital lifeline medicines because they are unaffordable” Hines contends.

“This calls for consensus building in which Representatives and Senators of both parties who support personal importation who should instruct their staffs to come together to identify what opportunities—and obstacles—face enactment of new, current legislation to lower prescription drug prices via personal importation; address such problems such as one in 10 Americans not being able to afford their medicines; and, to restrain the Food and Drug Administration from the seizure and destruction of medicines which can easily be identified as authentic, safe medicines.

“By acting in such a manner to meet their obligations to the American public, Congress can develop legislation in which personal importation will have a major role and will reflect the realities of the needs of Americans patients today, rather than simply appealing for the HHS Secretary to carry the water on this issue,” Hines concludes.

Daniel Hines
RxforAmericanHealth
636-399-2849
email us here


Source: EIN Presswire